Cytosorbents (CTSO) Prelim. Q3 Revenue Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
CytoSorbents (CTSO) PT Lowered to $10 at Cowen, Keeps 'Outperform'
October 13, 2021 5:50 AM EDTCowen analyst Joshua Jennings lowered the price target on CytoSorbents (NASDAQ: CTSO) to $10.00 (from $14.00) while maintaining an Outperform rating following results and FDA approval of the IDE for DrugSorb's U.S. trial.
The analyst commented, "CTSO reported preliminary 3Q revenue of $9.7M,... More
